<DOC>
	<DOCNO>NCT01348152</DOCNO>
	<brief_summary>The primary objective study evaluate improvement severity constipation ( Baseline Day 28 ) , determine constipation severity instrument ( CSI ) score [ 1 ] , compare placebo , follow total daily oral dose 15 g TU-100 administer 28 consecutive day adult subject functional constipation .</brief_summary>
	<brief_title>Effect TU-100 Patients With Functional Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Have severity constipation CSI score 25 74 point . 2 . Have ability orally ingest study medication , TU100 , SmartPill capsule . 3 . Be male female age 18 80 year old , inclusive . 4 . Provide write informed consent participation study full explanation study purpose procedure . 5 . If female childbearing potential sexually active : 1 . She must agree practice highly effective method birth control , include hormonal prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , participation trial 4 week receive last dose study drug 2 . She must negative serum pregnancy test randomization . 6 . If male sexually active female childbearing potential : 1 . He must agree use double barrier birth control study 4 week receive last dose study drug . 2 . He must donate sperm study 4 week receive last dose study drug . 1 . Presence stricture , fistula , physiological mechanical bowel obstruction . 2 . Presence implant portable electromechanical medical device . 3 . History gastric bezoar swallow disorder . 4 . History gastrointestinal surgery within 3 month screen . 5 . History bowel resection . 6 . Current pregnancy lactation . 7 . History clinically significant alcohol drug abuse within year screening . 8 . Have condition might adversely affect capacity participate study , include liver disorder ( serum alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] level exceed 2.5 time upper limit normal [ ULN ] ) , kidney disorder , heart failure , blood disorder , metabolic disorder . 9 . Be diagnosed cancer , ulcerative colitis , Crohn 's disease , diverticulitis , scleroderma , Hirschsprung 's disease , Chagas ' disease , multiple sclerosis , Parkinson 's disease , stroke , paraplegia , quadriplegia , insulindependent diabetes mellitus , untreated hypothyroidism , systemic psychiatric disorder may , opinion investigator , interfere evaluation TU100 . 10 . Be take medication follow : anticholinergic agents/medications anticholinergic effect ( list prohibit drug attach Appendix G ; antidepressant permissible patient 's symptom stable , dose NOT change course study ) , warfarin , prokinetics ( i.e. , Domperidone , Metoclopramide ) , narcotic analgesic , agent might interfere evaluation TU100 opinion investigator . 11 . Have history allergic reaction hypersensitivity ginseng , ginger , Sichuan pepper . 12 . Have severe dysphagia food pill . 13 . Have participate clinical study within 30 day enrol study . 14 . Be unsuitable participation trial reason , accord investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Gastric Emptying</keyword>
</DOC>